- Market Realist•13 hours ago
AstraZeneca’s stock value has increased 11.9% over the last 12 months. Analysts estimate that it has the potential to return 17.8% over the next 12 months.
- Zacks•7 days ago
GlaxoSmithKline (GSK) announced that its HIV-focused company, ViiV Healthcare has initiated a phase III program to support regulatory filings for a two-drug regimen of Tivicay and Epivir for the treatment for HIV-1 infection.
GlaxoSmithKline plc (GSK)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||44.04 x 500|
|Ask||44.18 x 500|
|Day's Range||44.20 - 44.50|
|52wk Range||37.24 - 45.58|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||2,775.62|
|Avg Vol (3m)||3,348,957|
|Dividend & Yield||2.20 (5.00%)|